Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...
On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform" rating to a "market perform" rating. BMO also lowered its 12-month price target for BioNTech from ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...
The scientific case rests on updated results from PRESERVE-003, a Phase 3 trial run with partner OncoC4. The study tested Gotistobart as a monotherapy against the chemotherapy agent Docetaxel in ...
The authors of a peer-reviewed study published last week in EXCLI Journal concluded that Pfizer and Israel’s Ministry of Health knew in early 2021 about a significant ‘cardiac event’ safety signal ...
The arrival of COVID-19 vaccines marked one of the fastest and largest medical mobilizations in modern history. Messenger RNA vaccines used ...
For BioNTech, the readout offers tangible evidence that its pivot toward oncology is producing results rather than just promises. The company has spent years signaling its intent to move beyond ...
4don MSN
BioNTech threw in the towel on its colorectal cancer vaccine trial. Should investors be worried?
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
Health Canada authorized Pfizer and BioNTech’s Omicron XFG-adapted COVID-19 vaccine, with availability expected through Canadian ...
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results